CASTLE Study
ALCMI’s inaugural, multi-center research project collects repeated tumor and and blood samples from advanced stage lung cancer patients. CASTLE provides molecular (genetic) testing for enrolled patients to ensure more informed patient and physician decision-making and to establish a lung cancer “standard of care.”
n contrast to the limited scope/duration of other research initiatives, the CASTLE study provides a foundational resource enabling scientists to ask and answer the next questions. Current CASTLE substudies include: identifying and targeting cancer stem cells; screening for activating mutations impacting patient immune responses to cancer cells; enabling early detection by screening for circulating tumor cells; and development and testing of anti-cancer vaccines. A
s the majority of CASTLE sites are community hospitals, ALCMI is delivering advancements to patients where they live and connecting front-line clinicians to leading academic-based researchers.
THIS STUDY IS NOW CLOSED TO ENROLLMENT.
